<DOC>
	<DOCNO>NCT01488318</DOCNO>
	<brief_summary>This single-arm , non-masked , open-label , Phase II study cetuximab + dasatinib recurrent Squamous Cell Carcinoma The Head Neck ( SCCHN ) recur cetuximab-containing therapy ( please see attached schema ) . The primary endpoint 12-week PFS .</brief_summary>
	<brief_title>Cetuximab Dasatinib Recurrent Squamous Cell Carcinoma</brief_title>
	<detailed_description>Patients must recurrent SCCHN may receive number prior palliative systemic therapy recurrent disease ( without cetuximab othr EGFR inhibitor ) . One prior curative regimen ( induction , primary postoperative chemoradiotherapy ) give AND patient expose cetuximab part prior potentially curative treatment.Those receive prior Src kinase inhibitor EGFR inhibitor cetuximab eligible . Patients test serum IL-6 . If IL-6 detectable , patient ineligible . If IL-6 detect , patient eligible study . Subjects 2 week post last dose Cetuximab receive initial load dose 400 mg/m2 cycle 1 , day 1 . Subjects receive Cetuximab within 2 week start study start Cycle 1 dose 250 mg/m2 . Dasatinib start 3 day initial cetuximab study dose cycle 1 ( i.e cycle 1 , day 4 ) , continue without interruption .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Inclusion : Patients must metastatic and/or recurrent SCCHN previously treat cetuximab . Undetectable baseline serum IL6 NOTE : This eligibility criterion apply patient enrol second , biomarkerenrichment stage trial . Measurable disease per RECIST 1.1 . Unlimited prior treatment radiation chemoradiotherapy Any number prior regimen recurrent metastatic SCCHN ( i.e . palliative treatment ) include cetuximab EGFR inhibitor Age &gt; 18 year ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % , see Appendix A ) . Life expectancy great 12 week . Patients must normal organ marrow function define : 1. absolute neutrophil count &gt; 1,200/µL 2. platelet &gt; 100,000/µL 3. total bilirubin within normal institutional limit 4 . AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal 5 . Creatinine 1.5 X normal institutional limit Ability understand willingness sign write informed Consent document . Patients take concomitant medication CYP3A4 inducer potent inhibitor try avoid take proton pump inhibitor H2 antagonists rest treatment period . The medication continue medically necessary use note . Sexually active woman childbearing potential must use effective method birth control course study , manner risk failure minimize . Prior study enrollment , woman childbearing potential ( WOCBP ) must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . In addition , men enrol study understand risk sexual partner childbearing potential practice effective method birth control . All WOCBP MUST negative pregnancy test prior first receive investigational product . If pregnancy test positive , patient must receive investigational product must enrol study . In addition , WOCBP instruct contact Investigator immediately suspect might pregnant ( e.g. , miss late menstrual period ) time study participation . Exclusion : Patients recover adverse event due prior agent . A minimum interval 3 week elapse prior chemotherapy cetuximab . A minimum 12 week elapse prior definitive radiotherapy , minimum 1 week elapse prior palliative radiotherapy . Patients may receive investigational agent within 4 week start trial . Patients untreated brain metastasis exclude clinical trial . History allergic reaction monoclonal antibody . Inability swallow oral medication ( unless patient use feed tube case eligible ) . Uncontrolled angina uncontrolled hypertension history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Bazett 's correction . Diagnosed suspected congenital long QT syndrome . Patients currently take drug generally accept risk cause Torsades de Pointes include : quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycins , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . Any uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , psychiatric illness/social situation would limit compliance study requirement . History significant bleeding disorder unrelated cancer , include : diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) , diagnose acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Squamous Cell</keyword>
	<keyword>Head Neck</keyword>
	<keyword>After Cetuximab Containing Chemoradiotherapy</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Metastatic</keyword>
</DOC>